AKT1 and neoplasm: The PI3K/AKT (protein kinase B) and the mammalian target of rapamycin (mTOR) signaling pathways (PI3Kγ/AKT/mTOR) were able to inhibit NF-κB activation and stimulate C/EBPβ activation, thereby promoting immune suppression during tumour growth.